SACHS
ASSOCIATES

SACHS BIOCAPITAL USA FORUM

FOR PHARMA-BIOTECH PARTNERING & INVESTMENT OPPORTUNITIES

21ST MARCH 2018 | NEW YORK ACADEMY OF SCIENCES | USA

CONFERENCE GUIDE

www.sachsforum.com

SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

SACHS BIOCAPITAL USA FORUM

FOR PHARMA-BIOTECH PARTNERING & INVESTMENT OPPORTUNITIES

21ST MARCH 2018

NEW YORK ACADEMY OF SCIENCES, USA

Sachs Associates are delighted to welcome you to the Sachs BioCapital USA Forum for pharma-biotech partnering & investment opportunities. Building on the success of Sachs Forums in Europe and the USA, we decided to combine the 2nd Neuroscience BioPartnering & Investment and the 5th Cancer BioPartnering & Investment forums and make one event - Sachs BioCapital USA Forum (BCUSA) that will take place on the 21st of March at the New York Academy of Sciences.

The BCUSA showcases biotechs with advanced therapeutics and brings them together with pharma partnering executives and institutional investors, bankers and advisers. The programme features panels on pharma-biotech dealmaking, advances in different therapeutic areas and a keynote and roundtable on investment. We anticipate up to 250 delegates and 25 company presentations (public and private) and an emerging company track.

GENERAL INFORMATION

- The registration desk will be open from 7.30 am, although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.
- Networking at the forum is facilitated by our online One-2-One meeting system, which is available to all participants.

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.

EVENTS DIARY

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com.

4TH ANNUAL
IMMUNO-ONCOLOGY: BD&L AND INVESTMENT FORUM

1ST JUNE 2018 • WALDORF ASTORIA CHICAGO HOTEL • USA

Taking place on the first day of ASCO, the 4th Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.

6TH ANNUAL
MEDTECH & DIGITAL HEALTH FORUM

3RD OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

This year again we will be holding our 6th Annual MT&DH Forum one day before our 18th Annual BEF Forum, on 3rd of October at the Congress Center Basel. The programme is designed to highlight the latest industry develop-ments and showcase emerging and innovative technology companies seeking finance and partnerships.

The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 250 delegates and 25 presenting companies plus presentations by seed companies.

18TH ANNUAL
BIOTECH IN EUROPE FORUM

4TH – 5TH OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

18th Annual BEF Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe's pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 650 delegates and over 100 presenting companies plus presentations by seed companies.

The forum will be held for the fifth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The programme will feature number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides all delegates access to our online one-to-one meeting system, allowing you to set up, accept or decline private one to one meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

NOUSCOM AG

ADRIAN WOOLFSON

Chief Medical Officer

Adrian Woolfson was previously Global Clinical Lead of Early and Late Stage Hematology/Immuno-Oncology at Pfizer Inc, New York, and Global Medical Lead at Bristol-Myers Squibb, Princeton, New Jersey. He was educated at King's College, London, Balliol College Oxford, and Gonville and Caius College Cambridge. His medical training was at the John Radcliffe Hospital, Oxford, and post-graduate training at Addenbrooke's hospital, Cambridge. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge, and Wellcome Trust Research Fellow at the MRC Laboratory of Molecular Biology, Cambridge. His doctoral thesis and post-doctoral fellowship were supervised by Nobel Prize-winner and inventor of monoclonal antibodies Dr. César Milstein. He has over 100 publications, including peer-reviewed articles and reviews in PNAS, Nature and Science, conference posters and oral presentations, book chapters, and patents.

CELLECTIS

ANDRÉ CHOULIKA

Chairman and Chief Executive Officer

André Choulika, Ph.D., is one of the founders of Cellectis and served as Chief Executive Officer since the company's inception in 1999. He is Chairman of the Board of Directors since 2011 and President of Calyxt since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children's Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +).

EXCELLENTIA GLOBAL PARTNERS

BETH JACOBS

Managing Partner

Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank, founded in 2008. Excellentia Global Partners works closely with early stage biotech and medical device companies, raising capital and enabling critical licensing and partnering with pharmaceutical and biotech companies. Prior to establishing Excellentia Global Partners, Beth was a General Partner at Bio-IB, a life science-focused investment bank in New York.

Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. Prior to 2003, Beth served as Senior Vice President for Laureate Education (NASDAQ: LAUR), a $3 billion market cap company in the education sector. She worked across all business units in a corporate development role, with a distinct focus on identifying and executing on opportunities in China.

Beth was Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group for over 9 years. She started her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers.

She currently serves on the Board of Directors of EF Foundation, a global educational services company based in Stockholm and Cambridge, Mass, the Supervisory Board of Genomic Vision (GV listed on Euronext Exchange /Paris in DNA analysis), founding Global Ambassador for Susan G. Komen for the Cure, Board member for the Harvard Kennedy

School of Government Women's Leadership Board, Director of the William J. von Liebig Foundation, Board of Governors of the New York Academy of Sciences where she serves as Chair of the Investment Committee, Governance and Executive Committees, and the Friends and Visiting Committee of the Ancient Near East Department of The Metropolitan Museum of Art. Previously, Beth served for 7 years as the Vice Chairman of the Friends of the Budapest Festival Orchestra.

Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, and a BA, cum laude, from Boston College. She also studied at Centre d'Etudes Internationale in Geneva, Switzerland. Beth is fluent in French.

NEA

BIBHASH MUKHOPADHYAY

Principal

Bibhash is a Principal at New Enterprise Associates (NEA), where he focuses on investing in emerging therapeutics and device companies, assisting them grow and create value. Previously, he was at AstraZeneca / MedImmune as an Associate Director of Business Development, where his responsibilities spanned end-to-end in the deal-making spectrum, from search and evaluation to transactions, with focus on the immune-oncology and immunology spaces. He started his career at Johnson and Johnson, where he held multiple Business Development roles, at different times, in Global Surgery, Oncology and Emerging Technologies. Bibhash's doctoral research work focused on pathophysiology of retinal diseases using tools of cell biology and mathematical modeling, during which he also consulted for venture funds and start-ups.

NEMUS BIOSCIENCE, INC.

BRIAN MURPHY

Chief Executive Officer & Chief Medical Officer

Dr. Murphy has more than 15 years experience in drug development and evaluation, both from the academic and industry perspective. He most recently served as the Chief Medical Officer of Eiger Biosciences. Previously, Dr. Murphy was Chief Medical Officer at ValeantPharmaceuticals International (VRX) where his responsibilities also included oversight ofGlobal Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then Vice President of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons at Hoffmann-LaRoche. Prior to joining industry, Dr. Murphy was Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. Dr. Murphy is board-certified in internalmedicine and completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. He went on to complete parallel fellowship tracts at Harvard Medical School, one in internal medicine/clinical epidemiology at the Massachusetts General Hospital and the other in medical ethics addressing issues of distributive justice and access to care. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.

PJT PARTNERS

BRUCE LEUCHTER

Managing Director

Dr. Bruce Leuchter is a Managing Director at PJT Partners where he provides M&A and capital markets advisory services to companies in the life science industry with a focus on the biotechnology sector. Dr. Leuchter is a physician by training and Neuropsychiatrist by specialty. He completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Dipolmate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a faculty appointment of Clinical Assistant Professor of Psychiatry. Dr. Leuchter's financial services experience, prior to joining PJT Partners, includes roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively. Given his background in neuroscience, he frequently advises companies developing technologies for diseases of the brain and nervous system. Dr. Leuchter co-founded Click Therapeutics, a digital medicine company which engineers, validates and commercializes digital therapeutics across disease areas with a focus on neuropsychiatry. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, and on the Leadership Council of the Life Science Institute at the University of Michigan.

MRL VENTURES FUND

CHRISTINE BRENNAN

Partner

Dr. Brennan has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Partner at MRL Ventures Fund (MRLV). She was previously on the board of Altimmune (NASDAQ:ALT) and an observer on the boards on a number of companies including ROX Medical, Innocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine. She is currently responsible for MRLV investments in Translate Bio and Alector.

Prior to MRLV, she was Principal at the Novartis Venture Fund from 2013-2017 and Chief Business Officer at Vitae Pharmaceuticals, Inc from 2010-2013. She also she held positions in business development and marketing at small and mid-size biopharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and completed post-doctoral research in developmental neurobiology from the National Institutes of Health.

MAXCYTE, INC.

DEBRA BOWES

EVP, Business and Strategic Development

Debra currently serves as EVP, Business and Strategic Development for MaxCyte.

In 2006, she started a consulting business, Chevy Chase BioPartners, specializing in Commercial Strategic Planning and Licensing for biotech/pharmaceutical companies.During this time she has held contract positions as interim CEO & CBO for CapGenesis Therapeutics and VP of Licensing and Commercial Strategy for CBLI Pharma. Prior to starting CCBP she was the Sr Director of New Product Planning for MedImmune where she built a department responsible for supporting the commercial and business planning aspects of MedImmune's R&D pipeline. Prior to MedImmune Debra held the position of Senior Director, Corporate Development for Amylin Pharmaceuticals. Previously, she spent several years at Pfizer Pharmaceuticals in Licensing and New Product Planning focusing on oncology. Serving as Worldwide Market Manager for Centocor, she was responsible for managing and expanding oncology licensing agreements with European and Japanese partners. Debra started her pharmaceutical career with Hybritech, Inc where she held positions of growing

responsibility in sales, marketing, market research and licensing.

Debra is a former President, current National Board Member and member of Nat'l Director Emeritus for Women in BIO. She has been an industry speaker since 2005 and currently serves on Industry Corporate Boards. Debra holds a Bachelor of Science degree in cell biology from the University of Cincinnati, a Medical Technologist (M.T.) certification from the American Society of Clinical Pathologists and an MBEE from John's Hopkins University.

AISLING CAPITAL, LLC

DENNIS PURCELL

Founder & Senior Advisor

Mr. Purcell is Founder and Senior Advisor to Aisling Capital LLC. Previously, he served as the Senior Managing Partner. Aisling Capital is a leading investment firm that invests in products, technologies, and global businesses across the Life Sciences industry. Aisling Capital has raised over $1.8 billion since inception. Prior to founding Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q"). While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and is actively involved with many of the industry's professional organizations. He has been a member of the Board of numerous private and public healthcare companies and currently serves as Executive Chairman of Poliwogg Holdings, a company devising new financial products for the healthcare industry. He also currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and the New York Investment Fund as well as a Senior Industry Advisor for Bioscience Managers Pty Ltd an Australian based specialist healthcare fund manager.

Mr. Purcell is a member of The University of Delaware Investment Committee, Harvard Kennedy School - M-R CBG Advisory Council, and the New York Leadership Council.

He received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.

PROMIS™ NEUROSCIENCES, INC.

EUGENE WILLIAMS

Executive Chairman

Eugene Williams is a life sciences entrepreneur and senior manager with 35+ years of experience.

He is currently the Executive Chairman and Co-Founder of ProMIS Neurosciences, a publicly traded company focused on neurodegenerative diseases.

ProMIS has a proprietary science platform that enables the rational drug design of antibodies which selectively target the toxic oligomer variant of proteins that mis-fold and drive diseases like Alzheimer's and ALS. ProMIS has validated assets targeting the oligomer forms of amyloid beta, TDP43, and SOD1, with discovery work ongoing identifying targets for alpha-synuclein and tau.

Prior to ProMIS, Mr. Williams was the CEO and Co-Founder of Dart Therapeutics (now called Akashi), an Orphan Disease drug development company focused on Duchenne Muscular Dystrophy. DART pioneered a novel business model – it was funded entirely by equity

investments from patient foundations. Mr. Williams was an SVP at Genzyme for nearly 10 years, with senior roles integrating commercialization, drug development, and deal making. He has also been a successful entrepreneur in healthcare services. He was a Co-founder and director of Adheris, which became the largest company in the patient adherence area. He started his career as a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was Co-Head of the Healthcare practice and spent extensive time on projects related to both speeding and improving the drug development process and commercialization strategies. Mr. Williams holds a B.A. from Harvard University and an M.B.A. from Harvard Business School.

ROCHE INNOVATION CENTRE

FIONA MACK

Director External Innovation

Dr. Fiona Mack is a Director of External Innovation located at Roche Innovation Center NY. In her current role she supports the scientific and strategic assessment of external pre-clinical and clinical opportunities to complement Roche's oncology portfolio. While at Roche, Fiona was also the Research Program Leader for the clinical collaboration with Oryzon Genomic to develop the novel LSD1 inhibitors for treatment of hematological and solid tumor indications. Prior to joining Roche, Fiona was a Principal Research Scientist at Pfizer Oncology. There she managed a team of scientists who were responsible for the evaluation and early development of novel platform technologies, including anti-sense therapeutics, T-cell engaging bi-specifics antibodies and antibody drug conjugates. Fiona received her undergraduate degree from Cornell University and her Ph.D from the University of Pennsylvania, where she investigated the regulation of hypoxic cell signaling during embryonic and cancer development.

AMARANTUS BIOSCIENCE HOLDINGS, INC.

GERALD COMMISSIONG

President & Chief Executive Officer

Mr. Commissiong is President & CEO, Co-Founder and a member of the Board of Directors of Amarantus Bioscience Holdings, Inc. Mr. Commissiong has been responsible for leading the Company's strategic transactions, licensing, research collaborations, mergers and acquisitions, and fund raising. He has raised over of $25 million to acquire and develop assets to build a robust therapeutics and diagnostics pipeline. Prior to becoming CEO in October 2011, Mr. Commissiong was the Chief Operating Officer. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.

DEFINED HEALTH, A CELLO HEALTH BUSINESS

GINGER JOHNSON

Chief Executive Officer

Ginger is CEO and CNS Practice Lead for Defined Health, where she manages core opportunity assessments and strategic consulting projects. Her background spans both the science and business of healthcare, ranging from basic scientific research to private equity investment and corporate development. Ginger was Vice President, Corporate Development at Skila (an e-Health company), and the Director of Life Science Research at Chase Capital Partners private equity firm (now JP Morgan Partners). Ginger was Associate Director of the Center for Biotechnology at Northwestern University and spent eight years in basic and applied scientific research, primarily in the field of Alzheimer's Disease, at the National Institute of Mental Health. Ginger holds BS in Molecular Biology from the University of Tennessee and a Ph.D. in Genetics from the George Washington University.

EMERALD HEALTH PHARMACEUTICALS, INC.

JIM DEMESA

Chief Executive Officer

Dr. DeMesa has 29 years of experience in biotech product development, clinical and regulatory management, and partnerships with pharmaceutical, biotech, and medical device companies. He has raised more than $150 million to advance product development into clinical stage, regulatory approval, and commercialization. He is the former CEO of two public biotech companies: Migenix and GenSci Regeneration Sciences (now part of Integra LifeSciences). Dr. DeMesa also currently serves as director for two biotech companies: OncoSec Medical (NASD:ONCS) and Induce Biologics. Previously, he was Vice President, Medical and Regulatory Affairs at Biodynamics International (now part of RTI Surgical) and Bentley Pharmaceuticals (now part of Teva Pharmaceuticals). Dr. DeMesa received his BA in Chemistry, MD, and MBA from the University of South Florida and did his medical residency at the University of North Carolina.

LSP

JOEP MUIJRERS

Portfolio Manager and Partner

Joep Muijrers, PhD, is Portfolio Manager and Partner at LSP (www.lspvc.com), a trans-Atlantic investor group with exclusive focus on life sciences and a track record dating back to the late 80-ies. Since he joined LSP in 2007, Joep has been responsible for investing in publicly-traded life sciences companies, several of which have been acquired by large pharmaceutical companies (Ablynx, Colucid, InterMune, Kite Pharma, ZS Pharma) and/or have grown to become leaders in their respective areas of activity (Argenx, Evotec, Genmab, GW Pharmaceuticals, MorphoSys, Neurocrine). Prior to joining LSP, he held the position of Director Corporate Finance and Capital Markets at Fortis Bank, currently part of ABN AMRO. Joep holds a Ph.D. degree in Molecular Biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and a Master's degree in Biochemistry from the University of Nijmegen, The Netherlands. He is currently a Director of Pantarhei Biosciences, the EMBL Alumni Association and serves on the Advisory Boards of Life Sciences Cares and CureSearch.

PSIOXUS THERAPEUTICS LTD.

KAREN LAROCHELLE

Chief Business Officer

Karen J. LaRochelle has broad biopharmaceutical strategy and collaborations experience. She spent 20 years with Bristol-Myers Squibb serving as Global Head of Negotiations and Head of Business Development following earlier positions in alliance management, strategy, analysis and finance. Karen also lead a successful consultancy providing business development expertise to leading biotechnology companies including Exelixis and Chase Pharmaceuticals. Karen has negotiated and executed transactions with biotechnology, pharmaceutical, technology and international companies, several in excess of $1 billion, across therapeutic areas including oncology, neuroscience, virology and cardiovascular. Karen received her MBA from Columbia University and a BS in Industrial Engineering from Lehigh University. She led the Business Development Advisory Board of New Jersey's Biotechnology Council (BioNJ), and currently serves on the Lehigh University Engineering Advisory Board.

JOHNSON & JOHNSON INNOVATION CENTER-BOSTON

KULDEEP NEOTE

Senior Director, New Ventures/Scout

Kuldeep Neote, Ph.D., is Senior Director at J&J Innovation Center-Boston, and is responsible for New Venture and Scouting opportunities in the areas of Oncology and Immunology in the East Coast. Dr. Neote is trained as a Molecule Biologist with an extensive background in drug discovery. He has been focused in the area of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Throughout his career, he has looked at creative scientific and business development collaborative and partnering opportunities that have resulted in tangible clinical translation of new scientific discoveries working in conjunction with academic and biotech companies. Formerly, Dr. Neote was Research Advisor/Director in Global External R&D at Eli Lilly in Indianapolis, IN. Prior to Eli Lilly, he was a Discovery Scientist in Pfizer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that lead to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the first chemokine receptors during his post-doctoral studies in Genentech. Dr. Neote earned her BSc. in Microbial and Cellular Biology at the University of Calgary, Calgary, Canada, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, Toronto, Canada, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay

PFIZER, INC.

LASZLO KISS

Global Neuroscience Lead, ES&I

Laszlo Kiss is the Executive Director, Global Neuroscience Lead in the External Science and Innovation department at Pfizer. Laszlo has over 20 years of drug discovery, development and management experience. He has a successful track record in leading CNS, CV and Rare Disease drug discovery programs from early exploratory research through clinical development. Prior to joining Pfizer, Laszlo held various roles of increasing responsibility at Bristol-Myers Squibb, Essen Biosciences and Merck & Co. Laszlo earned his Ph.D. in Physiology and Neurobiology from the University of Connecticut and completed his post-doctoral training in Neuroscience at the University of California at San Diego. He is the author of more than 50 scientific publications in peer reviewed journals, book chapters, abstracts and patents. Laszlo has served on grant review panels at the National Institutes of Health, National Institute of Neurological Disorders and Stroke.



APCETH BIOPHARMA GMBH

LUC ST-ONGE

Head of Business Development & Licensing

Luc St-Onge has over 20 years' experience in business development and IP in the biopharmaceutical industry. Prior to joining apceth Biopharma, Dr. St-Onge was Head of Business Development at Ganymed Pharmaceuticals during the acquisition of the company by Astellas Pharma for 1.3 billion. He is also a co-founder of ARRIDAD Therapeutics, a biotech company developing novel drugs for the treatment of diabetes and autoimmune diseases and was formerly Chief Business Office at Affectis Pharmaceuticals and Director of Diabetes research at Develogen. Dr. St-Onge is a molecular biologist by training, and has worked with adult and embryonic stem cells during his scientific career. He has published over 25 articles in top journals such as Nature, Oncogene, PNAS, and has filed numerous patent applications.

STALICLA SA

LYNN DURHAM

Chief Executive Officer

Lynn is a biotech entrepreneur and the founder of STALICLA SA. Her lifelong involvement with the Autism community has brought her to develop a unique patient centric vision of Drug Development to address the unmet medical needs of patients with Autism Spectrum Disorder. Fostering on a strong network within the neuroscience, clinical research and data science communities, she launched STALICLA in early 2017 and is leading its early fast-paced growth to bring personalized medicine to patients with ASD. Lynn has extensive experience in Business development and has worked in the past for the World Economic forum, venture capital & start-up promoting initiatives. Lynn holds a double degree in economic history and political sciences and a Master's degree from Rouen Business School. She has also received a Post Graduate Degree in Drug Discovery and Clinical Development from the Faculty of medicine of the University of Geneva.

BRISTOL-MYERS SQUIBB

MATTHEW RODEN

Head of Strategic Corporate Development, and Global BD Assessment

Matthew Roden, PhD, is Head of Strategic Corporate Development, and Global Business Development Assessment at Bristol-Myers Squibb, where he oversees the Mergers & Acquisition (M&A) and Search and Evaluation (S&E) teams. In this role, Matt works with leaders across the organization to recommend creative options and proactive strategies to expand the R&D and product portfolios. Prior to joining BMS, Matt was Sector Head of Biotechnology Equity Research at UBS, covering the technical, strategic, and financial outlook for biotech companies regardless of therapeutic area. Previously, he was a Senior Analyst covering biotechnology at J.P. Morgan, Bank of America Merrill Lynch, and launched his Wall Street career as an Associate at Credit Suisse First Boston. Matt holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, and earlier was a pre-doctoral clinical research fellow in immuno-oncology at the National Cancer Institute in Bethesda, MD.

JEFFERIES, LLC

MAURY RAYCROFT

Senior Biotech Analyst



EDISON GROUP

MAXIM JACOBS

Director of Healthcare Research

Maxim is Senior Healthcare Analyst at Edison Investment Research where he covers companies from all sub-sectors of healthcare. He joined Edison from Guidepoint Global, where he was a director of survey and tracker research, conducting extensive primary research across healthcare markets. He also brings more than 15 years' experience in equities to the healthcare team. Previously he was a senior healthcare analyst and therapeutic sector head at Ridgemark Capital and Broadfin Capital, and a healthcare analyst at Mehta Partners. Maxim is a CFA charter holder and graduated magna cum laude with a BA in Economics from the University of Pennsylvania.

VALOR MANAGEMENT S.A.

MICHAEL FARLEY

Director

Michael founded Valor Management in 2002, a business advisory servicing life science companies and investors in global markets. Prior to Valor, Michael managed technology and investment programs for the Canadian Department of Foreign Affairs and International Trade. He holds a PhD in the History and Philosophy of Science from the Université de Montréal (1986). Michael is fluent in several languages.

PFIZER, INC.

MONIKA VNUK

Executive Director, Business Development

Dr. Monika A. Vnuk leads business development activities for Pfizer Vaccines. Since joining Pfizer in 2008, Dr. Vnuk has been responsible for leading the evaluation, execution and negotiations of many business transactions, including licensing deals, collaborations, joint-ventures and mergers and acquisitions.

Before joining Pfizer, Dr. Vnuk was a vice president at Banc of America securities. During her time with Banc of America, Dr. Vnuk worked with life sciences companies helping clients complete initial public offerings, private placements and strategic transactions. Prior to her position at Banc of America, she was a Principal at Oxford Bioscience Partners, a venture capital firm focused on early stage biotechnology investments. During her five years with Oxford, Dr. Vnuk worked with the investment team in forming several biotechnology and medical device start-ups and helping portfolio companies complete private financing transactions. Prior to that job, Dr. Vnuk was a Fellow at the Health Care Entrepreneurship Program at Boston University.

Dr. Vnuk is a 2000 Inductee to the Alpha Omega Alpha Medical Honor Society. Dr. Vnuk holds a B.A. in Mathematics and Philosophy from Boston University and an M.D. from Boston University School of Medicine.

ABBVIE, INC.

MURALI GOPALAKRISHNAN

Head, Search & Evaluation - Neuroscience

Murali joined Abbott/AbbVie in 1993 and subsequently held various positions of increasing responsibility leading research programs and research teams in neuroscience, pain, renal and urology - advancing multiple clinical candidates across these therapeutic areas. He has extensively published in scientific journals and was inducted to the Volwiler Research Society in 2002. From 2009-2013, Murali took on the role as Head of the then newly formed Global External Research group, leading a team focused on developing external innovation strategies with various therapeutic areas, and enabling the identification, diligence and establishment of external collaborations around emerging science, targets, technologies and preclinical assets. He was also responsible for the leadership of AbbVie China R&D Center in Shanghai, since its inception in 2009 and subsequently led the Renal Discovery Therapeutic Area, advancing research programs internally, and via a network of external academic partnerships. Since 2015, he has taken on a leadership position within AbbVie's Search & Evaluation team, with responsibilities for accessing and advancing opportunities in in the Neuroscience Therapeutic area.

Murali obtained his undergraduate training in pharmacy from Banaras Hindu University, India and a PhD in pharmacology from the School of Pharmacy, SUNY at Buffalo, New York. He completed his post-doctoral training in molecular biology at the Baylor College of Medicine, Houston, Texas and has an MBA degree from the Lake Forest Graduate School of Management, Illinois.

ABBVIE, INC.

NIELS EMMERICH

Head, Search & Evaluation Oncology

Niels joined Abbvie in 2011 and has held several positions at AbbVie, including Global Commercial Leader for a late-stage oncology program, Director and Head of Commercial Business Development for Oncology, and most recently Senior Director and Head of Search and Evaluation, Oncology. Transactions that Niels was involved in in his current and previous role include acquisitions (Pharmacyclics, Stemcentrx), R&D collaborations and license agreements (Argen-X, CytomX, Dong-A-ST, Harpoon, M2Gen, MD Anderson PureMHC,

Turnstone, X-Chem,) and venture investments (eFFECTOR, Palleon, Artios, Carma).

Prior to joining AbbVie Niels was CEO of BioPheresis, co-founder and COO of immatics biotechnologies GmbH, and a strategic management consultant for McKinsey & Company.

Niels attended University of Tuebingen in Germany and received a Master's in Biology and a Ph.D. in Immunology.

ALETA BIOTHERAPEUTICS

PAUL RENNERT

President & Chief Scientific Officer

Paul Rennert is President & CSO of Aleta Biotherapeutics Inc., based in Natick MA. Aleta is developing transformative technologies for use in cellular therapeutics directed to the treatment of cancer. Paul's industry expertise covers bench to IND and clinical trial development of biological and small molecule drugs for oncology, autoimmunity, chronic inflammation and fibrosis, notably at Repligen Corp. and Biogen Inc. Since 2012 he has focused on building novel biotechnology companies and worked on the genesis of CoStim Pharmaceuticals with MPM Capital, joined with X-Chem Inc to spin out the asset-centric company X-Rx, founded Sugarcone Biotech LLC, and most recently, co-founded Aleta Biotherapeutics and Encipher Biotechnology. He is well known to the immuno-oncology community through his work with diverse biotech companies, academic centers and investors. His views on IO drug development strategy are widely followed on the sugarconebiotech.com blog, and through numerous invited talks. He has published and patented extensively; his most recent publication is the book "Novel Immunotherapeutic Approaches to the Treatment of Cancer".

TAPIMMUNE, INC.

PETER HOANG

President and Chief Executive Officer

Mr. Hoang brings over twenty years of investment banking, venture capital, immuno-oncology and public company executive management experience to TapImmune, serving most recently as Senior Vice President of Business Development and Strategy at Bellicum Pharmaceuticals. Previously, as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. Before joining MD Anderson, Mr. Hoang was a senior investment banker, most recently as Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group. He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.

TARGIMMUNE THERAPEUTICS AG

PETER KASH

Co-Founder and Vice-Chairman

Dr. Peter Kash is Co-founder and Vice-Chairman of TargImmune Therapeutics based in Switzerland. He also serves as Managing Director of Castle Hill Capital Partner Inc. He has co-founded more than a dozen biotech companies including: Edgemont Pharmaceuticals, Kite Pharma, and Intercept Pharmaceuticals, Keryx, ID Vaccines, Velcera.

Dr. Kash has worked on Wall Street for 30 years. He co-founded and financed PolaRx Biopharmaceuticals; developing the first cancer drug from China, Rrisenox approved by the FDA. From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton

Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo and in 2015 a Visiting Professor at Hebrew University

His education includes a B.S. in Management Science from S.U.N.Y. Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He holds a Doctorate in Education at The Azrieli Graduate School of Yeshiva University. Dr. Kash completed post graduate classes on Making Board's of Directors (both Profit and Non-for Profit) More Effective at Harvard Business School.

He has authored several books including the international best seller Make Your Own Luck, (Prentice Hall), now in 8 languages distributed in more than 30 countries worldwide. In 2007 he co-authored Freedom From Disease (St. Martin's Press) His newest book Take Two Tablets Medicine from the Bible was released in 2014 in Israel and released in 2016 in the U.S and China.

Peter was a television host for FNN's business program "International Spotlight," where he hosted this nationally syndicated show for 2 years and was a guest on CNN and Fox News, The Joey Reynolds Show, WB11, or with Dr. Oz on Oprah's Radio Show, etc.

VITALITY BIOPHARMA, INC.

ROBERT BROOKE

Director of Oncology Commercial Development

Robert Brooke is the CEO and co-founder of Vitality Biopharma, a drug development company dedicated to unlocking the power of cannabinoids for treatment of serious neurological and inflammatory conditions. Previously, he was the founder of a cancer drug development company that is now known as Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Mr. Brooke is also a co-founder and serves on a limited part-time basis as the CEO of Intervene Immune, Inc. From 2004 to 2008, he was an analyst with Bristol Capital Advisors, LLC, investment manager to Bristol Investment Fund, Ltd. During this period, Bristol financed over 60 public healthcare and life science companies, and was listed by The PIPEs Report in 2005 as being the most active investor in private placements by public biotechnology companies. Mr. Brooke has a BS in Electrical Engineering from Georgia Tech and an MS in Biomedical Engineering from UCLA.



REAL ENDPOINTS

ROGER LONGMAN

Chief Executive Officer

Mr. Longman is recognized as an expert in biopharmaceutical strategy and reimbursement and often speaks at key industry events organized by important trade organizations, investment banks, venture capital firms, and leading biopharma companies. His most recent focus has been on new value-based approaches to paying for drugs and diagnostics, harnessing tools and systems for objective, transparent analysis of drug value and economic impact. He is developing these initiatives in collaboration with major provider, payer, pharmaceutical and diagnostic, and patient organizations.

Mr. Longman has been involved with the health-care industry for more than 30 years. At his first venture, Windhover Information, he and his team created a number of industry-standard analytical sources, including must-read strategy publications such as IN VIVO and Sart-Up, the strategic transactions database and a major conference business for senior executives. The business was acquired by Elsevier where for the two years of his contract Longman ran the company's combined pharmaceutical business information group.

Mr. Longman lectures regularly at several leading universities and co-directed the Wharton-Windhover pharmaceutical program at The Wharton School. Mr. Longman completed his BA at Cornell University and an MA at the University of North Carolina at Chapel Hill, and then taught for three years at the European division of the University of Maryland.

ACURASTEM, INC.

SAM ALWORTH

Chief Executive Officer

Sam Alworth is the chief executive officer of AcuraStem Inc., a biotechnology start-up working to transform outcomes for patients with neurodegenerative disease. AcuraStem utilizes advanced stem cell technology and machine learning to study diseases of the central nervous system (CNS) using living neurons from current patients – a virtual nerve biopsy. AcuraStem's predictive platform has identified a novel ALS target and preclinical lead candidate. This work was heralded in the February 5, 2018 issue of Nature Medicine for its groundbreaking research. AcuraStem is partnering with patients and their clinicians, as well as drug discoverers, to evaluate disease progression and test existing FDA-approved therapeutics to find the most efficacious treatments to slow disease progression. AcuraStem strongly believes this approach will soon deliver new insights into the clinic, and new therapies for these challenging CNS disorders.

Alworth is also one of the company's four co-founders, along with Drs. Justin Ichida, Qing Liu and Paul August. He has over 15 years' experience in life science entrepreneurship, product management, R&D and business development, applying for and securing over $18M in private investment and non-dilutive government R&D funding. Alworth has the bioinformatics and machine learning expertise required to create innovative experiments using human cell models. He has proven expertise in managing large international, multidisciplinary scientific projects. He holds several U.S. patents and has contributed to multiple peer-reviewed scientific journals. Sam is fluent in Chinese, has a global perspective, and a deep passion for using technology to provide solutions for some of world's largest challenges.

GOODWIN PROCTER LLP

SARAH SOLOMON

Partner

Ms. Solomon represents biotechnology, pharmaceutical, medical device, diagnostic and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as co-development, joint research and development agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, distribution, supply, clinical trial, university licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and patent portfolio acquisitions). Ms. Solomon also counsels clients in connection with international transactions and relationships in North America, South America, Europe and Asia.

RAYMOND JAMES FINANCIAL, INC.

STUART BARICH

Managing Director

Stuart Barich joined Raymond James in 2015 as a Managing Director focusing on Life Sciences. Mr. Barich has participated in the successful completion of over 275 transactions during his career, covering a broad spectrum of equity and mergers and acquisitions. Prior to joining Raymond James, Stuart spent almost 10 years at Oppenheimer and five years at Leerink Swann completing numerous transactions for Biotechnology and Specialty Pharmaceutical companies. He previously directed the health care banking efforts at Oscar Gruss & Son and Auerbach, after beginning his career as a Corporate Finance Associate with Paine Webber. Mr. Barich has a BS in electrical engineering from the University of Rochester and an MBA with honors from Columbia Business School.

CANACCORD GENUITY, INC.

SUMANT KULKARNI

Managing Director, Research, Biotechnology

Sumant Kulkarni joined Canaccord Genuity in May 2017 as a New York-based Managing Director covering Biotechnology stocks. His initial research focus is on biotech companies within the central nervous system (CNS) space. Prior to that, Sumant was at Bank of America-Merrill Lynch where he covered biopharmaceutical stocks since 2005 as part of a top Institutional Investor-ranked team, and was most recently a director leading that firm's Specialty Pharmaceuticals franchise. He started his career on the sell-side covering the Life Science Services sector at Jefferies.

Sumant's background includes an MBA, an MS in chemical engineering and academic research in biomedical engineering (with a focus in oncology and cardiology) from The Ohio State University, and a bachelor's degree in chemical engineering from Bangalore University, India.

ABINGWORTH LLP

VINCENT MILES

Partner

Dr. Vincent Miles is a Partner at venture-capital firm Abingworth, with over 35 years' experience in the biotechnology industry. This includes positions as Senior VP of Business Development at Alnylam Pharmaceuticals (an Abingworth portfolio company); as VP of various business development, R&D and marketing functions at Millennium Pharmaceuticals, RiboGene and Pharmacia Biotech; as head of the technology transfer office at the Dana-Farber Cancer Institute; and as an R&D scientist at Amersham International. Vincent is on the boards of Hydra Biosciences, IFM Therapeutics and Personalis, having previously served on the boards of Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Magellan Diagnostics and PrimeraDx. He has a BSc in biochemistry and a PhD in biochemical embryology (molecular biology) from University College London.

TILRAY

WOODY PASTORIUS

Chief Operating Officer

Woody Pastorius is the President of Tilray North America and Chief Operating Officer of Tilray Global. With 30+ years of wide-ranging experience in healthcare, biotechnology, pharmaceuticals, and other sectors, he is a proven leader and builder of global businesses in various stages of growth.

ACURASTEM, INC.

ADDRESS
605 E. Huntington Dr.
Suite 103
Monrovia, CA 91016-6352
United States

WEBSITE
www.acurastem.com

E-MAIL
info@acurastem.com

PHONE
+1 213 290 0635

COMPANY TYPE
Private

SECTOR
Bioinformatics
Biotechnology

YEAR FOUNDED
2016

COMPANY PROFILE

AcuraStem Inc. is a biotechnology start-up working to transform outcomes for patients with neurodegenerative disease. AcuraStem utilizes advanced stem cell technology and machine learning to predict drug efficacy for diseases of the central nervous system (CNS) using living neurons from current patients – a virtual nerve biopsy. This precision medicine platform has identified a novel ALS target and preclinical lead candidate. This groundbreaking research from the lab of AcuraStem's President and co-founder Dr. Justin Ichida was heralded in the February 5, 2018 issue of Nature Medicine. AcuraStem is partnering with patients and their clinicians, as well as drug discoverers, to evaluate disease progression and test existing FDA-approved therapeutics to find the most efficacious treatments to slow disease progression. AcuraStem strongly believes this approach will soon deliver new insights into the clinic, and new therapies for these challenging CNS disorders.

MANAGEMENT TEAM

Samuel V. Alworth, CEO

Justin K. Ichida, President

Christopher Mathes, Head of Business Development

FINANCIAL SUMMARY

Launched by its co-founders in 2016, AcuraStem Inc. quickly became profitable and has a four year runway at present. AcuraStem revenues come from clinical and drug discovery partners, as well as non dilutive SBIR grants from the National Institutes of Health. In the period, 2017 - 2018 AcuraStem will see a 10-fold increase in revenue growth.

AcuraStem is developing a preclinical, small molecule therapeutic inhibitor of a novel ALS disease target recently disclosed in a groundbreaking Nature Medicine paper (http://rdcu.be/Gkpf) from the lab of AcuraStem's President and co-founder Dr. Justin Ichida.

SEEKING FINANCING

We are seeking a Series A round of financing to more rapidly scale our operations.

APCETH BIOPHARMA GMBH

ADDRESS
Max-Lebsche-Platz 30
Munich, 81377
Germany

WEBSITE
www.apceth.com

E-MAIL
contact@apceth.com

PHONE
+49 897 009 608

COMPANY TYPE
Private

SECTOR
Biotechnology
CMO
Regenerative Medicine

YEAR FOUNDED
2007

COMPANY PROFILE

Apceth's vision is to improve patients' lives with next generation cell therapies. Our programs aim to bring transformative and curative drugs for the treatment of inflammatory disease, autoimmunity, and cancer.

apceth-201 are genetically modified MSCs which expresses the immunomodulatory protein Alpha-1 Antitrypsin for the treatment of Graft-vs-Host-Disease, IBD, COPD and diabetes.

apceth-301 are MSCs that expresses a potent immunostimulatory "cocktail" of cytokines which locally activates the immune system to eradicate tumor cells. apceth-301 is being developed for Glioblastoma as well as other solid tumors such as colon, lung, and stomach cancers. Preclinical results suggest that apceth-301 induced long term anti-tumor immunity analogous to cancer vaccines and has synergy with CAR-Ts.

apceth is also a leading European Contract Development & Manufacturing Organization for the GMP manufacturing of complex cell and gene therapy products for clinical as well as commercial supply. apceth has a high market visibility and is recognized as one of Europe's pioneers in the field of cell-based therapies with a high international reputation for excellence, quality, and reliability. Our manufacturing facilities are located in Munich, Germany, in the heart of Europe which allows us to perform efficient and fast supply of client's product across the continent.

MANAGEMENT TEAM

Christine Günther, CEO, CMO, Managing Director

Dusan Kosijer, CFO & Managing Director

Felix Hermann, Head of R&D

Andreas Schmiede, BusinessUnit Head CDMO

Luc St-Onge, Head Business Development

PIPELINE PRODUCT 1:

Apceth-201/preclinical

PIPELINE PRODUCT 1:

Apceth-201 are genetically modified MSCs which expresses the immunomodulatory protein Alpha-1 Antitrypsin for the treatment of Graft-vs-Host-Disease, IBD, COPD and diabetes.

PIPELINE PRODUCT 2:

Apceth-301 / preclinical

PIPELINE PRODUCT 2:

Apceth-301 are MSCs that expresses a potent immunostimulatory "cocktail" of cytokines which locally activates the immune system to eradicate tumor cells. apceth-301 is being developed for Glioblastoma as well as other solid tumors such as colon, lung, and stomach cancers. Preclinical results suggest that apceth-301 induced long term anti-tumor immunity analogous to cancer vaccines and has synergy with CAR-Ts.

ADDRESS
Max-Lebsche-Platz 30
Munich, 81377
Germany

WEBSITE
www.apceth.com

E-MAIL
contact@apceth.com

PHONE
+49 897 009 608

COMPANY TYPE
Private

SECTOR
Biotechnology
CMO
Regenerative Medicine

YEAR FOUNDED
2007

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Apceth-201 / apceth-301

OPPORTUNITY 1:

Apceth is seeking a partner for the accelerated clinical development of apceth-201 for autoimmune diseases and apceth-301 for solid cancers.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

GMP manufacturing

OPPORTUNITY 2:

Apceth is also looking for new customers who need reliable and high quality GMP manufacturing of their cell therapies for clinical and commercial supply.

AZTHERAPIES, INC.

ADDRESS
222 Berkeley St
Boston, MA 02116
USA

WEBSITE
www.aztherapies.com

PHONE
+1 617 318 3411

COMPANY TYPE
Private

SECTOR
Biotechnology
Drug Development

YEAR FOUNDED
2011

COMPANY PROFILE

AZTherapies (www.aztherapies.com) is an advanced clinical stage pharmaceutical company based in Boston, MA. AZTherapies is using innovative approaches in the discovery, development and commercialization of novel Alzheimer's Disease and ischemic stroke treatments which could fundamentally improve patient treatment, quality of life and disease management. The company's lead program, ALZT-OP1, is a combination therapy comprising two re-engineered drugs with well-characterized safety profiles with intellectual property protecting drug combination, dosing, formulation and drug properties that will deliver the drugs to the blood and brain. The company platform also includes ALZT-OP2, a potential disease modifying AD drug treatment in advanced preclinical development, AZHALER-D, a single dose disposable novel inhaler in late stage development, and ALZT-QoL, a neurodegenerative drug treatment designed to improve the quality of life of AD patients using a compensatory M1 (a muscarinic receptor agonist) with ligand/receptor mechanisms to improve brain network connectivity. AZTherapies's drugs are based on technologies developed at Massachusetts General Hospital, a Harvard Medical School Teaching Hospital.

Biosceptre

ADDRESS
Jonas Webb Building
Babraham Research Campus
Babraham, Cambridge
CB22 3AT
United Kingdom

WEBSITE
www.biosceptre.com

E-MAIL
info@biosceptre.com

PHONE
+44 1223 496 090

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2003

BIOSCEPTRE INTERNATIONAL LIMITED

COMPANY PROFILE

Biosceptre is a UK headquartered biotech developing next-generation cancer therapeutics via exploitation of a novel target nfP2X7. Therapeutic modalities include vaccine, antibody and ADC.

Biosceptre is funded to complete a Phase 1 clinical trial of peptide vaccine BIL06v. Trial will begin recruitment in Q2/Q3 2018.

nfP2X7 is a variant of P2X7 discovered by Biosceptre to be present on a large majority of major cancers, as well as rare and pediatric cancers. Data indicating high prevalence (>50% on all tumours) on top 18 cancers, and high specificity to cancer tissues only, has been replicated externally.

Biosceptre's IP portfolio with respect to nfP2X7 is substantial, with over 100 patents granted globally.

MANAGEMENT TEAM

Gavin Currie, Chief Executive Officer

Sir Gregory Winter, CBE, FRS, FMedSci, HonFRCP, Chairman

Daniel Barton, Director Business Development

Shaun McNulty, Chief Scientific Officer

PIPELINE PRODUCT 1:

BIL06v

Phase I

PIPELINE PRODUCT 1:

BIL06v is a peptide cancer vaccine which recruits the individual's own immune system to generate antibodies that target specifically cancer cells expressing nfP2X7.

BIL06v is intended for use as therapy against the broad range of solid and haematological tumours seen to express nfP2X7.

PIPELINE PRODUCT 2:

BIL03s

Phase I regulatory approval received

PIPELINE PRODUCT 2:

BIL03s is a monoclonal antibody developed via phage display target specifically cancer cells expressing nfP2X7.

BIL03s is intended for use as therapy against the broad range of solid and haematological tumours seen to express nfP2X

CANTEX PHARMACEUTICALS, INC.

ADDRESS
1792 Bell Tower Lane
Weston, FL 33326
United States

WEBSITE
www.cantex.com

E-MAIL
info@cantex.com

PHONE
+1 954 315 3660

COMPANY TYPE
Private

SECTOR
Pharmaceuticals/Licensing

YEAR FOUNDED
2002

COMPANY PROFILE

My company, Cantex Pharmaceuticals, Inc., a clinical stage oncology company, is currently conducting a $40 million crossover financing round with the expectation of a public offering later this year.

Cantex has two products in phase II clinical development, both of which will provide data read-outs later this year. CX-01, a novel polysaccharide, for which positive phase II data is already available, is in a 75-patient randomized phase IIB clinical trial in acute myeloid leukemia and a phase II in refractory myelodysplastic syndrome. Dicopp™, Cantex's proprietary combination of disulfiram + copper, is in a phase II trial in glioblastoma and an investigator-initiated clinical trial in metastatic prostate cancer. In addition, with additional financing, Dicopp will begin clinical trials in metastatic pancreatic cancer and metastatic non-small cell lung cancer in 2018. All of our clinical trials are being conducted in major U.S. cancer centers, and are supported by both clinical experience and extensive literature from high quality medical journals.

MANAGEMENT TEAM

Stephen Marcus, MD: CEO

Neil Flanzraich: Executive Chairman

PIPELINE PRODUCT 1:

CX-01 is in phase II studies for AML and refractory myelodysplastic syndrome with positive data available.

PIPELINE PRODUCT 2:

Dicopp is a phase II oncology product in the clinic for glioblastoma and prostate cancer. We expect to initiate a phase II shortly in pancreatic cancer.

CUE BIOPHARMA, INC.

ADDRESS
675 West Kendall Street
Cambridge, MA 02142
United States

WEBSITE
www.cuebiopharma.com

PHONE
+1 617 949 2680

COMPANY TYPE
Public

TICKER
[NASDAQ: CUE]

SECTOR
Biotechnology

YEAR FOUNDED
2014

COMPANY PROFILE

Cue Biopharma is committed to bringing selective immune modulation to patients through our Cue Biologics platform. Our talented scientists are led by an experienced management team and supported by leading scientific and clinical advisors with deep expertise in the design and clinical development of protein biologics to treat cancer and autoimmune diseases. Together, we are developing novel, targeted therapies aimed at overcoming many of the challenges facing prevailing immunotherapeutics. We are headquartered in Kendall Square, Cambridge, MA.

PIPELINE PRODUCT 1:

CUE-101 Preclinical

PIPELINE PRODUCT 1:

CUE-101 is a fusion of a variant form of the cytokine Interleukin-2 ("IL-2") and a pMHC derived from the human papilloma virus E7 protein (HPV-E7). It is a single, covalently-assembled biologic designed to target and activate T cells specific to HPV-driven cancers. We believe CUE-101 offers significant advantages over current therapies and has the potential to provide patients with a more effective and safer alternative in treating their HPV-driven cancers. Our preclinical data, including animal models of HPV positive cancer, have generated highly encouraging results supporting strong efficacy as a monotherapy and synergy with approved checkpoint therapies.

Amarantus BioScience

ADDRESS
953 Indiana St
San Francisco, CA 94104
United States

WEBSITE
www.amarantus.com

PHONE
+1 415 688 4484

COMPANY TYPE
Public

TICKER
[OTCMKTS: AMBS]

SECTOR
Biotechnology
Diagnostics
Pharmaceuticals/Licensing
Regenerative Medicine

YEAR FOUNDED
2007

ELTO PHARMA (AN AMARANTUS COMPANY)

COMPANY PROFILE

Amarantus Bioscience Holdings (AMBS), a JLABS alumnus company, is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS also owns approximately 79.25 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.

MANAGEMENT TEAM

Gerald E. Commissiong: Co-Founder, President & CEO

Elise Brownell, PhD: Sr. Vice President of Project Management and Operations

Angela Sachdeva, CPA: VP Finance

John Commissiong, PhD: Co-Founder, Chief Scientific Officer, Director

FINANCIAL SUMMARY

Amarantus is a small-cap publicly traded Company seeking to raise capital for its subsidiaries as independent, stand-alone companies.

PIPELINE GRAPHIC

PIPELINE PRODUCT 1:

Eltoprazine: Phase 2b in Parkinson's Levodopa-induced Dyskinesia

PIPELINE PRODUCT 2:

Engineered Skin Substitute: Phase 2/3 Pediatric Severe Burns

PIPELINE PRODUCT 3:

Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF): Preclinical for Glaucoma, Retinitis Pigmentosa and Retinal Artery Occlusion

EMERALD HEALTH PHARMACEUTICALS, INC.

ADDRESS
Vancouver
Canada

WEBSITE
www.emeraldpharma.life

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2017

COMPANY PROFILE

Emerald Health Pharmaceuticals (EHP) is a private drug development company focused on patented non-psychotropic cannabinoid analogues for the treatment of inflammatory, auto-immune, neurodegenerative, fibrotic, and metabolic diseases. The Company's portfolio of over twenty patented molecules are chemically-modified derivatives of cannabidiol (CBD) and cannabigerol (CBG), specifically designed to improve the therapeutic properties of these natural compounds by addressing multiple biological targets and physiologic pathways that have been demonstrated to play key roles in specific central nervous system (CNS), auto-immune, inflammatory, metabolic, and fibrotic diseases. The first two selected product candidates from this portfolio of molecules (EHP-101, a CBD analogue, and EHP-102, a CBG analogue) are being developed to address unmet medical needs in the treatment of multiple sclerosis, scleroderma, Huntington's Disease and Parkinson's Disease. EHP expects to begin human trials on EHP-101 in 2018 and on EHP-102 in 2019.

MANAGEMENT TEAM

Jim DeMesa, MD, MBA (CEO)
Eduardo Munoz, MD, PhD (CSO)
Alain Rolland, PharmD, PhD (VP, Product Development)
Jill Broadfoot (CFO)
Nancy Coulson (VP, Regulatory and Quality Affairs)
Mari-Luz Bellido, PhD, MBA (VP, European Operations)
Bernie Hertel (VP, Investor Relations)

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

Name: EHP-101 (or VCE-004.8 in the scientific literature)
Stage: GLP Preclinical Development (human development to being in 2018).
Indications: Multiple Sclerosis and Scleroderma

PIPELINE PRODUCT 1:

EHP-101 is an orally-formulated drug candidate. The active pharmaceutical ingredient is a patented cannabidiol (CBD) derivative (new chemical entity) that has a unique mechanism of action as a dual PPARγ and CB2 modulator, as well as a HIF activator.

emerald HEALTH PHARMACEUTICALS

ADDRESS
Vancouver
Canada

WEBSITE
www.emeraldpharma.life

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2017

PIPELINE PRODUCT 2:

Name: EHP-102 (or VCE-003.2 in the scientific literature)

Stage: Formulation and manufacturing development

Indications: Parkinson's disease and Huntington's disease

PIPELINE PRODUCT 2:

EHP-102 is a drug candidate in which the active pharmaceutical ingredient is a patented cannabigerol (CBG) derivative (new chemical entity).

OPPORTUNITY 1:

EHP is currently preparing for a pre-IPO financing round of approximately $10m.

HEMISPHERX BIOPHARMA, INC.

ADDRESS
860 N. Orange Ave
Suite B
Orlando, FL 32801
United States

WEBSITE
www.hemispherx.com

E-MAIL
info@hemispherx.net

PHONE
+1 407 286 5207

COMPANY TYPE
Public

TICKER
[NYSEAMERICAN: HEB]

SECTOR
Biotechnology

YEAR FOUNDED
1990

COMPANY PROFILE

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.

The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.

The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

MANAGEMENT TEAM

Thomas K. Equels, M.S. J.D., Executive Vice Chairman, Chief Executive Officer, President

Adam Pascale, CPA, Chief Financial Officer

David R. Strayer, M.D. , Chief Scientific & Medical Officer

Peter W. Rodino III, J.D., Executive Director for Governmental Relations, General Counsel, Secretary

Wayne Springate , Senior Vice President of Operations

INNOVUS PHARMACEUTICALS, INC.

ADDRESS
8845 Rehco Road
San Diego, CA 92121
United States

WEBSITE
www.innovuspharma.com

PHONE
+1 858 964 5123

COMPANY TYPE
Public

TICKER
[OTCMKTS: INNV]

SECTOR
Medical Devices
Pharmaceuticals/Licensing

YEAR FOUNDED
2010

COMPANY PROFILE

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence. The company's pipeline products include FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; Xyralid, a lidocaine based cream for the relief of pain and symptoms caused by hemorrhoids; AllerVarx, a patented formulation produced in bilayer tablets; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

OTHER SECTOR

OTC Consumer Care Products

MANAGEMENT TEAM

Bassam Damaj, Ph.D - President & CEO

Randy Berholtz, JD/MBA - General Counsel and SVP of Corporate Development

Rauly Gutierrez, CPA - VP of Finance

Robert Verfurth - VP Sales & Marketing

FINANCIAL SUMMARY

Revenues

2015: $0.75M

2016: $4.8M

2017E: $10M

PIPELINE GRAPHIC

PRODUCT	INDICATION	PROJECTED
Xyralid® Suppositories	Hemorrhoids	H1 2018
Musclin™	Muscle Growth	H2 2018
UriVArx™-UTI Strips	UTI Detection	H2 2018
GlucoGorx™ Supplement	Glucose Management	H2 2018
GlucoGorx™ Glucometer	Blood Glucose Measurement	H2 2018
Vesele® - NO Strips	Saliva Nitric Oxide Measurement	H2 2018
Regenerum™	Cachexia or Wasting Syndrome	2019

LB PHARMACEUTICALS, INC.

ADDRESS
575 Madison Avenue
10th Floor
New York, NY 10022
United States

WEBSITE
www.lbpharma.us

E-MAIL
info@lbpharma.us

PHONE
+1 646 588 8175

COMPANY TYPE
Private

SECTOR
Pharmaceuticals/Licensing

YEAR FOUNDED
2015

COMPANY PROFILE

LB is focused on the multi-billion dollar US antipsychotic market and is developing a proprietary, patented version of amisulpride. Amisulpride is a successful anti-psychotic drug approved in Europe with millions of prescriptions filled throughout Europe/CIS/PacRim yearly comprising a market share within schizophrenia of 5-10% (depending on the country).

Well-controlled trials stretching back twenty years have documented amisulpride's effective treatment of the negative symptoms of schizophrenia as well as depressive disorders. More specifically, the data shows that amisulpride is one of the most effective antipsychotics in the world with no statistically significant difference in efficacy between amisulpride and the two drugs that currently comprise 40% of the US market (olanzapine and risperidone).

LB Pharma has changed the chemical structure of amisulpride to create a novel asset that could improve its efficacy and/or improve safety. In pre-clinical testing to date, results show that LB-102:

1) Has a CNS receptor binding profile that matches amisulpride, specifically slightly higher affinity at D2/D3 receptors

2) Has an oral pharmacokinetic profile in mice and rats that matches amisulpride

3) Has better membrane permeability than amisulpride

4) Are as efficacious or more efficacious than amisulpride in rat models of schizophrenia

5) Has a 14-day toxicity profile in rats that matches amisulpride (MTD of 200 mg/kg/day)

If approved by the FDA, LB-102 would be the first benzamide atypical approved for the US market. We believe the target market within the US schizophrenia market would mirror that of the EU, where amisulpride holds a 5-10% market share. Wtih 3 million US patients, a 2% market share would equate to a more than $1B/year revenue product.

MANAGEMENT TEAM

Zachary Prensky, CEO

Dr. Andrew Vaino, CSO

Vincent Grattan, Co-Founder, BoD Member

Marc Panoff, CFO

Edmund Sullivan, Early stage investor & BoD Member

Our Scientific Advisory Board includes:

Dr. John Kane, Chair, Psychiatry @ Zucker Hillside Hospital

Dr. Stefan Leucht, Department of Psychiatry & Psychotherapy, Technische Universtat, Munchen Germany

Dr. Ira Glick, Professor of Psychiatry and Behavioral Sciences, Stanford University School of Medicine

ADDRESS
575 Madison Avenue
10th Floor
New York, NY 10022
United States

WEBSITE
www.lbpharma.us

E-MAIL
info@lbpharma.us

PHONE
+1 646 588 8175

COMPANY TYPE
Private

SECTOR
Pharmaceuticals/Licensing

YEAR FOUNDED
2015

FINANCIAL SUMMARY

LB was founded in late 2015 and has closed 3 rounds of financing totalling $2m. Our lead investor in our last round was Rivopharm, SA, a Swiss pharmaceutical company with the leading position worldwide in the manufacture and marketing of amisulpride.

PIPELINE PRODUCT 1:

LB-102, or N-methyl amisulpride, is our lead compound. It is currently in pre-clinical development. We expect to complete our IND enabling studies by years end.

PIPELINE PRODUCT 1:

LB-102 is a patented analogue to amisulpride that is designed to mimick amisulpride's superior safety & efficacy in the treatment of schizophrenia while at the same time improving its bioavailability (resulting, we believe, in lower effective doses).

MaxCyte®

ADDRESS
22 Firstfield Road
Suite 110
Gaithersburg, MD 20878
United States

WEBSITE
www.maxcyte.com

PHONE
+1 301 944 1700

COMPANY TYPE
Public

TICKER
[LON: MXCT]

SECTOR
Biotechnology

YEAR FOUNDED
1998

MAXCYTE, INC.

COMPANY PROFILE

MaxCyte is a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners unlock the potential of their products and solve development and commercialization challenges.

MaxCyte is developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges.

NEMUS BIOSCIENCE, INC.

ADDRESS
600 Anton Blvd
Suite 1100
Costa Mesa CA
United States

WEBSITE
www.nemusbioscience.com

E-MAIL
hello@nemusbio.com

PHONE
+1 949 396 0330

COMPANY TYPE
Public

TICKER
[OTCMKTS: NMUS]

SECTOR
Biotechnology

YEAR FOUNDED
2011

COMPANY PROFILE

NEMUS Bioscience Inc. is a life-science, biopharmaceutical company focused on discovering, developing and commercializing cannabinoid-based therapeutics. These molecules display multi-functional activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. NEMUS is developing novel and proprietary classes of product candidates that have a global patent footprint with a goal of enhanced chemical engineering, leading to more predictable bioavailability and pharmacokinetics resulting in optimized efficacy and safety.

NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS.

ADDRESS
Bäumleingasse 18
Basel, CH-4051
Switzerland

WEBSITE
www.nouscom.com

E-MAIL
info@nouscom.com

PHONE
+41 61 201 1831

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

NOUSCOM AG

COMPANY PROFILE

Nouscom is a neoantigen vaccine company headquartered in Swizerland, with operations in Rome and New York. It's first two clinical studies in man utilize an off-the-shelf neoantigen vaccine in dMMR/MSI CRC in combination with immunotherapy, and a personalized vaccine in select checkpoint-sensitive solid tumors. Nosucom has a state-of-the art vaccien manufactureign facility in Rome, and is unique in being able to manufacture and administer a personaliozed vaccine within 5 weeks from the time of biopsy. Nosucom was foudned by a group of seasoned entrepreneurs, who sold their last company to GSK for Euro 300M. Nosucom is positioned to become a best-in-class neoantigen vaccien company, and its off-the-shelf vaccien is first-in-class. The company is funded by Abingworth, 5AM Ventures, Versant and LSP.

MANAGEMENT TEAM

Alfred Nicosia CEO
Marina Udier COO
Adrian Woolfson CMO
Elisa Scarselli CSO

FINANCIAL SUMMARY

Euro 54M raised. Versant, Abingworth, 5AM, LSP

FINANCIAL SUMMARY

Nous-209
Ph1
dMMR/MSI mCRC

PIPELINE PRODUCT 1:

Off-the-shelf neoantigen vaccine

PIPELINE PRODUCT 2:

PEV
Ph1
Personalized vaccine for immunogenic tumors

PIPELINE PRODUCT 2:

Personalized neoantigen vaccine

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Not currently looking for fudning

PROMIS™ NEUROSCIENCES, INC.

ADDRESS
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E6
Canada

WEBSITE
www.promisneurosciences.com

COMPANY TYPE
Public

TICKER
[TSX:PMN.TO]
[OTCQB:ARFXF]

SECTOR
Biotechnology

YEAR FOUNDED
2015

COMPANY PROFILE

ProMIS™ Neurosciences, Inc., is publicly traded on the TSX (ticker symbol: PMN.TO) and the OTCQB (Ticker ARFXF). ProMIS discovers and develops monoclonal antibodies that selectively target the toxic oligomers that drive neurodegenerative diseases such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). ProMIS's lead program PMN310 has shown scientific evidence of potentially superior therapeutic potency to Biogen's aducanumab in AD.

PIPELINE PRODUCT 1:

PMN310 - monoclonal antibody selectively targeting toxic oligomers of amyloid beta, preclinical development

PIPELINE PRODUCT 1:

PMN310 was designed to be superior to Biogen's aducanumab, taking advantage of recent advances in the understanding of Alzheimer's disease and applying ProMIS proprietary science capabilities. Many mroe advanced amyloid targeted therapies were designed based on the assumption that amyloid plaque was the pathogen and the target. Leading AD experts now know that amyloid toxic oligomers are the pathogen and should be the target for therapy. PMN310 has scientific evidence showing greater selectively for the toxic oligomer than aducanumab, as well as better binding response to toxic oligomers found in cadaveric brain homogenate. In addition, PMN310 was designed to avoid the dose limiting toxicity (ARIA-E) aducanumab faces. Evidence suggests PMN310 will be able to dose significantly higher without the side effect. Combined, these suggest much higher therapeutic potency than aducanumab. PMN310 is on track to be in the clinic with Phase 1 data from patients in early 2020, when aducanumab's pivotal trials read out

PIPELINE PRODUCT 2:

ProMIS has a portfolio of monoclonal antibodies that address the root cause of ALS - mis-folded toxic oligomers of TDP43 and SOD1. We are actvely seeking licensing partners for these assets.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

TDP43 and SOD1 antibodies

STALICLA

ADDRESS
Campus Biotech Innovation Park
Avenue de Secheron 15
1202 Genève
Switzerland

WEBSITE
www.stalicla.com

E-MAIL
Lynn.durham@stalicla.com

PHONE
+41 78 812 68 98

COMPANY TYPE
Private

SECTOR
Biotechnology
Bioinformatics
Diagnostics

YEAR FOUNDED
2017

STALICLA SA

COMPANY PROFILE

STALICLA SA is a Swiss based autism spectrum disorder (ASD) focused, data guided, drug development biotech company. Today patients with autism spectrum disorder account for 1-1.5% of the world population. The condition remains a high unmet medical need. STALICLA has taken a unique approach to bringing personalized medicine to patients with ASD. It has developed an innovative algorithm based platform (DEPI) that uses robust sets of clinical signs and symptoms with big data analytics to identify subgroups of patients with ASD. By identifying these subgroups, STALICLA is advancing repurposed drugs that provide more effective, personalized treatment options. STP1, STALICLA's first therapeutic package, addresses a uniquely characterized sub-group of ASD patients which represent 15% of the total ASD population.

MANAGEMENT TEAM

Management team Lynn Durham, CEO and Founder
Joseph Wettstein, Ph.D. - Acting Chief of Development and Strategy
Luigi Boccuto, MD - Chief Scientific Officer
Jean-Marc Hyvelin, Ph.D. - Chief operating officer Scientific Committee
Stephane Baudouin - Ph.D.
Denis Jabaudon - MD, Ph.D.
Walter Kaufmann - MD, Ph.D.
Christian Luscher - MD. Luca Santarelli - MD Board of Directors
Lynn Durham, Chairman of the Board
Katya Tsaioun, Board member
Benjamin Dubois, Secretary of the Board
Hugo Ferreira, Observer

FINANCIAL SUMMARY

Successful multi million initial financing round with Biotech Experienced investors
Round A - Q3- Q4 2018 - CHF 15 million
Round B - expected 2021 - CHF 50 - 70 million
IPO - 2023
Market entrance - targeted 2025

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

DEPI (Data EndoPhenotyping Patient Identification): STALICLA's innovation engine beta version

STALICLA

ADDRESS
Campus Biotech Innovation Park
Avenue de Secheron 15
1202 Genève
Switzerland

WEBSITE
www.stalicla.com

E-MAIL
Lynn.durham@stalicla.com

PHONE
+41 78 812 68 98

COMPANY TYPE
Private

SECTOR
Biotechnology
Bioinformatics
Diagnostics

YEAR FOUNDED
2017

PIPELINE PRODUCT 1:

DEPI is an algorithm conceived as a mathematical probabilistic model that summarizes large databases in interpretable manner. DEPI's operating software evidences commonalities between ASD big data and non ASD biomedical data. Commonalities are then filtered through personalized patient data. The novelty of DEPI does not solely stand in applying big data resources to clinical development but in doing so by integrating clinical data that had previously not been considered in ASD (e.g. sets of phenotype specific signs and symptoms). This allows to establish therapeutic target hypotheses, and use these to identify safe repositionable drugs.

PIPELINE PRODUCT 2:

STP1 (STALICLA Therapeutic Package 1) - pre-clinical

PIPELINE PRODUCT 2:

STALICLA's first therapeutic package (STP1) is intended to serve a well-defined subgroup of the ASD population, so-called ASD Phenotype 1 (ASD Ph1). This sub-population is characterized by sets of signs and symptoms and by a lower level of a specific biomarker.

STP1 comprises:

- a companion diagnostic, which permits the identification of ASD Ph1 patient
- a patented combination of two repurposed drugs
- a monitoring assay

STALICLA's patented therapeutic compounds consist of a combination of two repurposed drugs, aiming to restore several intracellular processes.

TAPIMMUNE, INC.

ADDRESS
5 West Forsyth Street
Suite 200
Jacksonville, FL 32202
United States

WEBSITE
www.tapimmune.com

PHONE
+1 904 862 6490

COMPANY TYPE
Public

TICKER
[NASDAQ: TPIV]

SECTOR
Biotechnology

YEAR FOUNDED
1991

COMPANY PROFILE

TapImmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company's next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company's off-the-shelf vaccines boost patients' immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to work with 80% of the population.

TapImmune is advancing two clinical stage T-cell vaccine candidates in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from FDA Fast Track and Orphan Disease Designation. The company is working in collaboration with industry and clinical leaders including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca.

MANAGEMENT TEAM

Peter L. Hoang - President & CEO

Glynn Wilson, Ph.D. - Chairman & Strategic Advisor

Richard Kenney, MD, FACP - Acting Chief Medical Officer

Michael J. Loiacono - CFO

TILRAY

TAPIMMUNE

ADDRESS
1100 Maughan Rd
Nanaimo, BC V9X 1J2
Canada

WEBSITE
www.tilray.ca

E-MAIL
tilray@tilray.ca

PHONE
+1 844 845 7291

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2011

COMPANY PROFILE

A proud company of firsts, Tilray is a global leader in medical cannabis cultivation, processing, distribution and research. The company currently serves tens of thousands of patients in ten countries across five continents. In December 2016, Tilray became the first medical cannabis licensed producer in North America to be GMP-certified in accordance with the European Medicines Agency's (EMA) Good Manufacturing Practice (GMP) standards. In 2017, the company became the first to export medical cannabis from North America to the European Union, Latin America, Australia, and New Zealand. Currently, Tilray is also the only company to have a federal cannabis cultivation license from two countries (Portugal and Canada) on two continents.

VITALITY BIOPHARMA, INC.

ADDRESS
1901 Avenue of the Stars
2nd Floor
Los Angeles, CA 90067
United States

WEBSITE
www.vitality.bio

E-MAIL
info@vitality.bio

PHONE
+1 530 231 7800

COMPANY TYPE
Public

TICKER
[OTCMKTS: VBIO]

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2013

COMPANY PROFILE

Vitality Biopharma is unlocking the power of cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory conditions, such as pediatric forms of inflammatory bowel disease.

Vitality has developed a class of oral cannabinoid pharmaceuticals known as cannabosides, which are colon-targeted and designed to avoid the psychoactive central effects of THC.

Cannabinoids are well known for their pain relief and anti-inflammatory effects, and placebo-controlled clinical trials have shown positive effects for induction of remission of drug-resistant Crohn's disease. Vitality's colon-targeted cannabinoids are intended to amplify these benefits through local delivery that also avoids all psychoactivity (i.e. no sedation). For this reason, the compounds may be especially useful in pediatric applications.

Vitality has also recently discovered direct anti-microbial and anti-cancer effects of cannabinoids, which may enable new applications of cannabosides for treatment of colorectal cancer and modulation of the gut microbiome.

MANAGEMENT TEAM

Robert Brooke, CEO & Co-Founder

Avtar Dhillon MD, Chairman & Co-Founder

Brandon Zipp Ph.D., Director, R&D, Scientific Co-founder

Richard McKilligan, JD, MBA, Controller & Counsel

FINANCIAL SUMMARY

Financial Highlights - Recent financing (Dec. 2017): $1.4M in common stock & warrants

PIPELINE GRAPHIC

Drug	Clinical Indications	Status
VBX-100	Inflammatory bowel disease (inducing remission), irritable bowel syndrome, narcotic bowel syndrome	Phase 1a/1b Trial to complete in 1st half 2018
VBX-210	Inflammatory bowel disease (maintaining remission), irritable bowel syndrome, opiate-induced bowel dysfunction, C. difficile infection, colorectal cancer	Preclinical
Additional Cannabinoid Formulations	Complex/refractory or neuropathic pain (substitution therapy for opioid painkillers), Huntington's disease, multiple sclerosis & rare white matter disorders, Guillain-Barré	Observational clinical studies to initiate in 1st half of 2018

PIPELINE PRODUCT 1:

VBX-100 (THC prodrug)

PIPELINE PRODUCT 1:

VBX-100 is a prodrug of THC (Marinol or dronabinol), and as a result, it may be developed using a 505(b)(2) regulatory path. VBX-100 is a cannaboside, a new class of cannabinoid glycoside compounds developed by Vitality that includes prodrugs of THC, CBD, and other cannabinoids.

ADDRESS
19 Firstfield Road,
Suite 100B
Gaithersburg, MD 20878
United States

WEBSITE
www.vlptherapeutics.com

PHONE
+1 240 801 4456

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

VLP THERAPEUTICS

COMPANY PROFILE

VLP Therapeutics is developing next generation virus-like particle vaccines against infectious disease and cancer. The Company's proprietary i-VLP (inserted alpha VLP) technology allows for efficient antigen delivery and demonstrates high titers. The company is headquartered in Gaithersburg, Maryland.

MANAGEMENT TEAM

Wataru Akahata, CEO, CSO

Jacob Licht, COO

FINANCIAL SUMMARY

Angel-funded, $4M in non-dilutive funding

PIPELINE PRODUCT 1:

VLPM01 Malaria Vaccine - Entering phase 1/2a in 2018

PIPELINE PRODUCT 1:

VLPM01 is a pre-erythrocytic malaria vaccine containing circumsporozoite protein (CSP) antigens and targets Plasmodium falciparum.

PIPELINE PRODUCT 2:

Dengue Vaccine - preclinical

PIPELINE PRODUCT 2:

A novel tetravalent dengue VLP vaccine with demonstrated the vaccine efficacy in mice and nonhuman primates

SUPPORTING ORGANISATIONS

BIOPARTNER

www.biopartner.co.uk

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, members receive extra benefits and support to effectively trade overseas.

SUPPORTING ORGANISATIONS

BIOTECHGATE

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

SUPPORTING ORGANISATIONS

Citigate Dewe Rogerson

CITIGATE DEWE ROGERSON

www.citigatedewerogerson.com

Citigate Dewe Rogerson is one of the most respected names in communications. We are experts in our fields, combining the expertise of bankers, fund managers, in-house investor relations, former journalists and creative communications professionals as well as sector and transaction specialists.

We are City-based but our business and perspective are international. We serve over 500 clients from new start-ups to some of the world's largest listed companies, governments and other organisations from our offices in London and in the US, Europe, the Gulf and Asia.

SUPPORTING ORGANISATIONS

EDISON

EDISON

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison's largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

SUPPORTING ORGANISATIONS

FREEMIND
Non-Dilutive Funding Experts

FREEMIND

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations. FreeMind's knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of xperts will assist in making non-dilutive funding a key tool in a long-term financial strategy.

SUPPORTING ORGANISATIONS

INSTINCTIF PARTNERS

INSTINCTIF PARTNERS

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

SUPPORTING ORGANISATIONS

SWISS BIOTECH™ National Thematic Network

SWISS BIOTECH

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland's profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.Swiss Biotechs' mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

SUPPORTING ORGANISATIONS

TIBEREND STRATEGIC ADVISORS, INC.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics.We work with both public and private emerging growth companies:

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances

SACHS ASSOCIATES

www.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on bio-pharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:

ONLINE ONE-2-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides all delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company position in this market. Sponsorship of any of our events allows you to raise your company's profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

- Conference Sponsor – including workshops and social events
- Exhibition stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com.

SACHS

ASSOCIATES

www.sachsforum.com